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Abstract  
The presence of circulating permeability factors (cPFs) has been hypothesized to be associated with 
recurrence of focal segmental glomerulosclerosis (rFSGS) in renal allografts. The available methods to 
detect cPFs are complex, not easily repeatable and inappropriate to represent the anatomical characteristics 
of the three-layer glomerular filtration barrier (GFB). Here we describe a novel method which measures the 
permeability to bovine serum albumin (BSA) through a three-layer device (3LD). The 3 layers comprise: 1. 
conditionally immortalized human podocytes (HCiPodo), 2. collagen type IV coated porous membrane and 
3. human glomerular endothelial cells (HCiGEnC). Using this method, we found that sera from all rFSGS 
patients increased albumin permeability, while sera from non recurrent (nrFSGS) and genetic (gFSGS) 
forms of FSGS did not. The mechanisms underlying the increase of albumin permeability are probably due 
to  endothelial cell damage as an initial event, which was demonstrated by the decrease of  Platelet 
endothelial cell adhesion molecule (PECAM-1 or CD31), while the podocytes’ expressions of synaptopodin 
and podocin were normal.  Furthermore, we also found that the plasmapheretic treatment (PPT) eliminated 
the effect of increasing BSA permeability in sera from rFSGS patients. These preliminary data suggest that 
our in vitro GFB model could not only be useful in predicting the recurrence of FSGS after renal 
transplantation (RTx), but also be a valuable in vitro model to study podocyte and endothelial cell biology.    
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Introduction 
Primary focal segmental glomerulosclerosis (pFSGS) is a glomerular disease of unknown etiology, often 
characterized by heavy proteinuria, which in more than 50% of cases does (do) not response to the available 
therapies and progresses  toward end stage kidney failure [1-2]. It has long been hypothesized that the 
presence of circulating permeability factors (cPFs) which damage the glomerular filtration barrier (GFB) 
could contribute to the pathogenesis of  pFSGS [3].This hypothesis was based on the frequent recurrence of 
FSGS after renal transplantation  (RTx, 30-50%), the reported proteinuria  resolution when an FSGS  kidney 
is transplanted in an unaffected  recipient,  the appearance of proteinuria in the newborn of a mother affected 
by FSGS, the regression/reduction of proteinuria after plasmapheresis (PP)  in some affected patients  [4-
12].   
The traditional method to determine the circulating permeability factors was based on the measurement of 
albumin reflection coefficient with isolated rat glomeruli [13], but this method is very complex and requires  
animal sacrifice. Pegoraro et al proposed a simpler method using cultured rat glomerular epithelial cells 
grown on the Millicell filters, which allow sampling of apical and basolateral media. Through measuring the 
125
I-labeled human serum albumin across the epithelial cell monolayer, they tested the circulating 
permeability activity of sera from idiopathic nephrotic syndrome patients [14]. In a recent paper, Kachurina 
et al described a novel method based on cultured mice podocytes challenged with sera from FSGS patients, 
using immunofluorescence microscopy followed by computerized image-processing analysis [15]. More 
recently, Srivastava et al developed a reporter-based assay, using transfected podocyte cells for the study of 
activated genes after exposure to the plasma from recurrent FSGS (rFSGS) patients [16]. However the main 
limitation of all these models, except the first one [13], is that the assays are based on only one epithelial 
monolayer, which is far from  the in-vivo physiological structure of GFB which is a three-layer structure 
with glomerular endothelial cells,  podocytes and the basement membrane in between.  
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 Here we described a method of co-culture of conditionally immortalized human podocytes and glomerular 
endothelial cells on the opposite of a porous membrane, which does not rely on special instruments nor on 
the synthesis of devoted biomaterials, so it may be widely adopted by the scientific community and is more 
easily performed than the original method based on isolated rat glomeruli [13]. Moreover this device not 
only permits us to study separately the events occurring in podocytes and/or endothelial cells, but also to 
detected the albumin permeability activity of sera from patients through a simple colorimetric analysis of 
BSA across the three-layer device (3LD).  
 
Materials and Methods 
Patient samples 
Seven  recurrent FSGS (rFSGS), 10 non recurrent FSGS (nrFSGS),  and 5 genetic forms of FSGS (gFSGS)  
sera from adult and pediatric patients (Table 1), who signed an informed consent [M. 02. F (A)], were 
collected in Adult and Pediatric Nephrology, Dialysis and Renal Transplant Units (Fondazione Ca' Granda 
IRCCS Ospedale Maggiore Policlinico- Milan). 8 healthy blood donor sera were collected in the Blood 
Transfusion Center of the same hospital. rFSGS was diagnosed when renal transplanted (RTx) patients with 
a histological confirmed diagnosis of FSGS in their native kidneys (5 patients) or with a history of steroid 
resistant nephrotic syndrome (SRNS) as the cause of native kidney failure (2 patients), developed  
significant proteinuria (> 3 g/day) and/or had histologic finding of FSGS at the renal graft biopsy  within the 
first year  after RTx. All the seven rFSGS had been submitted to PP treatment. In each rFSGS patient, pre- 
and post-PP sera were collected before and immediately  after PP treatment. 
In 6 of rFSGS cases,  the blood sample  was collected at the first or second PP therapy, performed 
immediately after the FSGS recurrence (within first 2 months), while in one patient (subject number 2), 
transplanted in 2011 and affected by an early FSGS recurrence, who required  chronic PP therapy, the blood 
collection was performed after 6 years of RTx. PPs were performed using albumin in most patients (subjects 
1, 2, 4, 5, 6), while plasma was utilized in patients 3 and 7.   
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 Serum samples were processed under sterile laminar flow hood (Heraeus, Hanau, Germany) and divided 
into small volume aliquots to avoid multiple freeze/thaw cycles and stored at -80°C. Before use, sera were 
thawed on ice immediately before experiment and diluted to 2% with cell culture medium. 
Cell cultures 
Conditionally immortalized human glomerular endothelial cells (HCiGEnC) and conditionally immortalized 
human podocytes (HCiPodo) (both from University of Bristol, Bristol, UK) were cultured as previously 
described [17, 18]. Briefly, for propagation, cells were grown at 33°C and 5% CO2 in endothelial growth 
medium 2-microvascular (EGM2-MV, Lonza, Walkersville, MD USA) containing 5% fetal calf serum 
(FCS) and growth factors as supplied, excepting vascular endothelial growth factor (VEGF) or in RPMI-
1640 medium containing 10% Fetal bovine serum (FBS), 5 μg/ml transferrin, 5 ng/ml sodium selenite, 0.12 
U/ml insulin, 100 U/ml penicillin, 100 mg/ml streptomycin (all from Sigma Aldrich, Milan, Italy). 
HCiGEnC and HCiPodo were utilized within 35 and 20 passage respectively.  
In-vitro model of glomerular filtration barrier (GFB) and assessment of permeability 
The in-vitro model of GFB is assembled according to a modified previously described methodology [19]. 
Briefly, using the Millicell hanging cell culture inserts with Polyethylene Terephthalate (PET) microporous 
(1 μm diameter) membrane (Millipore, Milan, Italy) coated on both sides with collagen type IV (Sigma), 
75,000 endothelial cells are  seeded on the lower side of the membrane and allowed to adhere to it for 4 h; 
then  the endothelial cells are  cultured in EGM2-MV medium containing 5 ng/ml of VEGF (Sigma)  at 
37°C and,  after 3 days, 65,000 podocytes are  seeded on the upper side of the membrane and cultured by 
their own medium. Podocytes and endothelial cells are co-cultured in their respective medium for an 
additional 5 days before experiment. To assess albumin permeability, after carefully washing 3LD with 
PBS,  RPMI-1640 only and RPMI-1640 plus 40 mg/ml BSA  are added in the upper  (podocyte) and lower  
(endothelial) compartment respectively.  After 2 hours incubation, the concentration of BSA is assessed in 
the upper compartment and taken as the basal level (BSAb). Thereafter, both compartments are emptied, 
washed again, and the lower compartment is filled with the experimental solution (i.e.: adriamycin at 
concentration of 0.8, 1.4 and 2 µM; or 2% serum to be tested, added to the medium), while the upper 
compartment with podocytes’ medium. The 3LD is then incubated for 24 hours with adriamycin or 48 hours 
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with patient’s serum. At the end of the incubation, the two compartments are emptied again, washed and 
BSA permeability assay is repeated as before (BSAexp).  The changes in BSA permeability are expressed 
as: (BSAexp-BSAb)/BSAb %. BSA has been measured by spectrometry using the DC protein assay kit 
(Bio-Rad, Milano, Italy). Each patient serum and each ADR concentration were tested in 3 different devices 
contemporarily and the results are expressed as mean ± SD. Healthy control experiments were obtained by 
incubating the device with sera from 8 healthy blood donors in triplicate. (Fig.1 A) 
Immunofluorescence  
After removing the membrane from the insert using a sharp scalpel and placing it onto a microscope slide, 
cells to be studied (pocodytes or endothelial cells) were washed and fixed with 10% neutral buffered 
formalin for 10 min at room temperature, permeabilized with 0.3% Triton X-100 in PBS. Sequentially, the 
cells are  incubated overnight at 4 °C with the primary antibody (rabbit anti-CD31, 1:100, Abcam, 
Cambridge, UK; rabbit anti-synaptopodin, 1:50 and rabbit anti-podocin, 1:50, Sigma), followed by the 
addition of the appropriate fluorescent-labelled secondary antibody (Alexa Fluor 488 goat anti-rabbit IgG, 
1:200   Invitrogen, S. Giuliano Milanese, Italy) and 4',6-diamidin-2-fenilindolo (DAPI, 1:1000, Sigma). The 
specificity of the primary antibody was demonstrated by the lack of staining after substituting the primary 
antibody with proper control immunoglobulin (rabbit IgG isotype control, Zymed, California, USA 
(Supplementary Fig.1). Images were acquired by AxioObserver microscope and recorded by AxioVision 
software 4.8 (all from Zeiss, Milan, Italy). The parameters for image acquisition were first established with 
cells exposed to healthy sera and then were applied to all samples treated with patients’ sera.  The 
percentage of the membrane surface covered by cells and mean fluorescence intensity (FI) from 10 images 
of each sample were analysed by Image J software. The results were expressed as percentage of FI of 
healthy controls. 
Statistical analysis 
Data are presented as mean ± SD. At least three replicates were performed for each sample. Two-tail 
Student's t test was used for analysis of data when two groups of data were compared. ANOVA test was 
applied when comparing more than 2 groups of data. P values <0.05 were considered significant. 
Results  
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Assembly of the in-vitro model of GFB 
Based on our previously published method [19], we successfully substituted the immortalized mouse 
podocytes and mouse capillary endothelial cells with the conditionally immortalized human podocytes and 
human glomerular endothelial cells. As shown by Fig. 1 B, immunofluorescence staining of cells grown on 
the membrane with anti-CD31, a specific endothelial cell marker (left) and anti-podocin, a specific podocyte 
marker (right) demonstrated the homogeneous formation of the cell monolayer on the two different sides of 
the membrane (average area covered by endothelial cells and podocytes 91±4.9% and 89.9±1.9 %, 
respectively) (Fig. 1B).  
Validation of the albumin permeability assay 
For validation of the albumin permeability assay, we used adriamycin to induce cell damage, which in turn 
must result in increasing the BSA passage across the three-layer structure. In physiological conditions 
(medium alone), BSA permeability was 1.3 ± 4.1%.  Incubation with adriamycin at concentration of 0.8, 1.4 
and 2 µM for 24h induced a statistically significant and dose dependent increase of BSA permeability as 
compared with cells incubated with medium alone (18.95 ± 2.05%, *p<0.05; 31.5±1.98%, **p<0.01; 
41.75±5.59%, **p<0.01 respectively) (Fig.1C). Immunofluorescence Staining showed that treatment with 
ADR induced both endothelial cells and podocytes damage(s). As seen in supplementary Fig.2, there was a 
remarkable decrease of CD31 expression on endothelial cells, while podocytes presented not only the 
decrease of podocin and synaptopodin immunostaining intensity but also the changes of their distribution 
(podocin: from cytoplasmic and membrane expression to weak cytoplasmic expression; synaptopodin:  from 
cytoplasmic, along acting filaments and cell processes expression to cortical, near to the cell membrane 
expression.).   
Effects of sera from patients with diverse forms of FSGS on the GFB 
To check if the in-vitro GFB model can be used to detect the circulating permeability factors, we added in 
the endothelial cell compartment the sera from 7 patients with early post-transplant rFSGS, 10 from 
nrFSGS, 5 from pediatric patients with gFSGS and 8 from healthy blood donors (HBD).  As shown in 
Fig.2A, all rFSGS samples increased significantly the BSA permeability (27 % ± 5.27), while the nrFSGS, 
gFSGS and HBD samples did not (-2.1 % ± 6.2; 3.0 % ± 3.5; 0.4% ± 5.2 respectively). The differences 
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between the effects on BSA permeability of rFSGS vs nrFSGS, gFSGS and HBD sera were statistically 
significant (**P < 0.01). 
To verify the reproducibility of BSA permeability assay, serum from 3 patients with rFSGS was used in 
three independent different experiments at two weeks distance of each other, each experiment was 
performed in triplicate at the same time. as shown in Fig.2B, the variation among experiments was not 
statistically significant (Sample1: 40.3 ± 7.2%; 34.7± 6.5%; 32.2 ± 0.9%; ANOVA P = 0.39. Sample 2: 
23.6±6.3; 23.8±1.1; 20.1±3.3; ANOVA P=0.69. Sample3: 20.6±1.5; 17.9±2.2; 20.8±1.1; ANOVA P=0.22). 
Effects of pre- and post- plasmapheresis sera on the GFB 
To verify if PP can change the GFB permeability to albumin, we compared the effects of sera collected pre- 
and post PP from the 7 rFSGS patients. As shown in Fig.2C, incubation with pre-PP sera induced a 
consistent increase in BSA permeability, but this effect was no longer evident with sera collected 
immediately after PP treatment. (26.1 vs -9.5; 23.6 vs -9.4; 32.3 vs -6.7; 20.6 vs -6.0; 28.7 vs -0.63; 22 vs 
1.5; 22.6 vs 1.7). The differences between pre- and post PP sera were statistically significant (*P < 0.05; ** P 
< 0.01). 
Immunofluorescence staining 
Then we assessed if the changes in BSA permeability induced by rFSGS sera were associated with any 
change in the expression of some molecules specific for either podocytes or endothelial cells. Fig.3A 
showed that sera from the majority of patients with rFSGS (5 out of 7) induced an evident decrease of 
Platelet endothelial cell adhesion molecule (PECAM-1 or CD31) expression on endothelial cells, while sera 
from nrFSGS and gFSGS did not;  the normalized mean fluorescence intensity (% of healthy sera) was:  
rFSGS, 47.7% ± 34.6; nrFSGS, 100% ± 9.7; gFSGS, 98.1% ± 12.5 respectively) (Fig.3B). Staining with 
anti-synaptopodin presented the expression along acting filaments and cell processes (arrows) (Fig.4 A-D, I) 
and anti-podocin showed a   filamentous cytoplasmic, cell surface and cell processes(e)? distribution 
(arrows) (Fig.4 E-H, J). Incubation on endothelial cells? with sera from different patients, which is 
presumably the initial event occurring in vivo, didn’t change the intensity or the distribution of these 
molecules.     
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Discussion 
We successfully assembled a system of HCiPodo and HCiGEnC co-culture which mimics the in-vivo GFB 
structure (Fig.1A, B), whose permeability to BSA was highly increased in a dose-dependent way by adding 
adriamycin (Fig.1C), a chemotherapeutic nephro-toxic drug already utilized for inducing chronic proteinuric 
nephropathy in rodents  [20, 21].  
Although some clinical aspects might predict recurrence of FSGS after RTx [2], a reliable and repeatable 
laboratory methodology could be useful in the clinical practice. Testing the sera drawn from 7 patients with 
rapid rFSGS after RTx (from 5 to 150 days), we found a significant increase of BSA permeability in all 
these patients (Fig.2A). The genetic or secondary forms of FSGS are not expected to recur at all (genetic) or 
need a long time before recurrence (metabolic) after RTx [4]. In fact, we were not able to find any evident  
change in BSA permeability with sera collected from those patients, some of whom received a RTx, but did 
not recur, suggesting a high specificity of the test for the rFSGS (Fig.2A).  
The repeatability of our method was confirmed by the overlapping results obtained by three independent 
experiments performed in the same serum sample (Fig. 2B).  
PP has been reported to have beneficial effects in some patients with rFSGS [5, 8, 9]. In fact, sera collected 
before PP in 7 rFSGS patients induced a consistent increase in BSA permeability; these effects were no 
longer evident when 3LD was challenged with sera collected immediately after PP (Fig. 2C). These results 
reinforce the suggestion of the presence of cPFs in most patients with FSGS who recurred after RTx [4-12]. 
Although it has long been hypothesized that rFSGS is the consequence of podocyte damage due to various 
pathogenic CPFs [22, 23, 24], the initial events occurring when the glomerular endothelial cells come in 
contact with the hypothesized cPFs  are still unknown. Fig.3 showed that 48 hours incubation on endothelial 
cells with the majority of rFSGS patients sera (5 of 7) induced a noticeable decrease of CD31, while at the 
same time point the podocytes still presented  a normal expression of synaptopodin (Fig.4 A-D, I) and 
podocin (Fig.4 E-H, J). CD31 is a cellular adhesion and signalling receptor that is highly expressed at 
endothelial cell–cell junctions and have implications in the maintenance of vascular barrier integrity [25]. 
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More than 15 years ago, Ferrero and colleagues reported that PECAM-1-specific monoclonal antibody 
augments transit of 125I-labelled albumin across endothelial cell junctions, both in cultured cells and in 
mice [26]. Our results suggest that the hypothesized cPFs might trigger the pathological events first by 
damaging the endothelial cells, followed by an increase of GFB permeability and consequently a podocyte 
damage. It is worth underlining that not all sera from our rFSGS patients (2 of 7) induced a decrease of 
CD31 expression, implying that the possible mechanism(s) may well be characterized by different 
pathogenic pathways. So, the purpose for future research could be that of better understanding and defining 
these possible different pathways.       
In conclusion, these preliminary data suggest that the assessment of BSA permeability by our in vitro 3LD 
could be a valuable method for predicting the recurrence of FSGS after RTx.  Moreover this device could be 
a worthwhile instrument to study separately the biology of podocytes and endothelial cells and their cross-
talking during physiological and pathological processes.   
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Legends to Figures 
Fig. 1. Co-culture assembly and BSA permeability after adriamycin (ADR) treatment. A) Schematic 
drawing of the preparation of the in vitro GFB and BSA permeability assay. HCiGEnC and HCiPodo were 
grown on the opposite of the PET membrane coated both side with Collagen type IV. The three-layer 
structure divided the system into a lower (endothelial) and upper (podocyte) compartment. For BSA 
permeability assay, the lower compartment was filled with 40 mg/ml of BSA in cell culture medium while 
the upper compartment with medium alone. B) Immunofluorescence staining with anti-CD31 (left, green), 
anti-podocin (right, green) and 4', 6-diamidin-2-fenilindolo (DAPI, blue) on cells grown on the membrane. 
Scale bar: 20 µm. C) Incubation on endothelial cell compartment with ADR at different concentration for 
24h induced a dose-dependent increase of BSA permeability. * P < 0.05, **p<0.01. Each bar represents the 
mean ± SD of triplicate experiments.  
 
 Fig. 2. Effect of sera incubation on BSA permeability. A) Effect of sera from patients with diverse forms 
of FSGS on BSA permeability. Incubation on lower (endothelial) compartment with 2% of sera from 
recurrent (n = 7), non recurrent (n = 10), genetic (n = 5) FSGS and  healthy blood donors (n = 8) for 48h. 
BSA permeability was consistently increased in all the 7 rFSGS patients, without any relevant increase in 
the other cases. Tx-rFSGS, renal transplantation with recurrent FSGS; Tx-nrFSGS, renal transplantation 
without recurrent FSGS; nTx-gFSGS, non renal transplantation with genetic FSGS; HBD, healthy blood 
donor. B) Reproducibility. Variation of BSA permeability among three independent experiments with serum 
from each of 3 rFSGS patients. The results, expressed as percentages of basal condition, demonstrate no 
statistically significant difference. E1, E2, E3: experiment 1, 2, 3. C) Effect of pre- and post-plasmapheresis 
sera on BSA permeability. Incubation of sera collected immediately before and after PP showed the 
complete disappearance of the effect of pre-PP sera on albumin permeability by PP. All results were 
expressed as percentages of basal condition.  Each bar represents the mean ± SD of triplicate experiments. * 
P < 0.05, ** P< 0.01 
Fig. 3. Immunofluorescence staining on endothelial cells after sera incubation. A) Representative 
images of CD31 expression. After 48 hours incubation of  endothelial cell compartment with 2% sera from 
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recurrent (n = 7), non recurrent (n = 5), and  genetic (n =5) FSGS patients, CD31 expression was 
considerably decreased in 5 out of 7 rFSGS patients, while there were no evident change in all the others. B) 
Semi quantitative analysis of the mean fluorescence intensity (FI) showed that sera from majority of rFSGS 
patients decreased the mean FI, while sera from nrFSGS and gFSGS did not. The results were expressed as 
percentages of FI of healthy control.  Scale bar: 50 µm. ** P< 0.01 
Fig. 4. Immunofluorescence staining on podocytes after sera incubation. Representative images of 
expression of synaptopodin (A-D) and podocin (E-H).  After 48 hours incubation of the endothelial cell 
compartment with 2% sera from recurrent (n = 7), non recurrent (n = 5), genetic (n = 5) FSGS patients, the 
intensity as well as the distribution of synaptopodin and podocin were not changed. Semi quantitative 
analysis of FI of synaptopodin (I) and podocin (J) showed that there were no significant variations among 
the different groups. Scale bar: 50 µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
